CliffBio
small molecule

ODEFSEY

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

Loss of exclusivityFebruary 2033latest FDA-listed patent expiry
CompanyGilead Sciences →View the full company profile on CliffBio

Drug detail

Brand nameODEFSEY
Active ingredientEMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE
Strength200MG;EQ 25MG BASE;EQ 25MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2016
Marketing statusRX

Listed patents

PatentExpiresType
8754065*PEDFebruary 2033—
9296769*PEDFebruary 2033—
9296769August 2032substance, product
8754065August 2032substance, product

More from Gilead Sciences

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ODEFSEY patent cliff — loss of exclusivity February 2033 | CliffBio